Overall, our data on humoral response profiles confirm that the anti-native gliadin immune response is not predictive by itself of the progression to CeD, since it may be present independently of the activation of the pathogenic mechanism mediated by tissue transglutaminase. The gene discussed is TGM2; the disease is cranioectodermal dysplasia.